Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology · Invasive Ductal Carcinoma

Understanding Your Diagnosis: Invasive Ductal Carcinoma

At a Glance

Invasive ductal carcinoma is breast cancer that has grown from a milk duct into nearby breast tissue, but the word invasive does not by itself mean distant spread or stage IV. Tests for stage, lymph nodes, grade, ER, PR, and HER2 guide treatment.

Being diagnosed with breast cancer is a life-altering moment that often brings a wave of complex emotions, from fear to confusion. It is important to know that you are not alone; you have been diagnosed with the most common form of breast cancer, and the medical community has a deep, evidence-based understanding of how to treat it [1][2].

What is Invasive Ductal Carcinoma (IDC)?

Invasive Ductal Carcinoma (IDC) is a type of breast cancer that began in the milk ducts and has “invaded” or spread into the surrounding breast tissue [3][4]. You may also see this referred to in your pathology report as Invasive Breast Carcinoma of No Special Type (IBC-NST). This is the modern medical term used by the World Health Organization (WHO) [5].

The word “invasive” does not mean the cancer has already spread to distant organs or that it is Stage IV. It simply means the cells broke out of the milk duct into the local breast tissue. Staging tests and lymph-node evaluation determine whether the disease has spread further.

The term “No Special Type” sounds like a placeholder, but it is actually a specific classification. It means the cancer cells do not have the unique, specialized features seen in rarer types of breast cancer (like “mucinous” or “lobular” cancers) [5][6]. Because it is the most common form—accounting for approximately 80% of all invasive breast cancer cases—it is the subtype doctors have researched and treated the most [1][7].

Invasive vs. Non-Invasive: Understanding the Difference

A common source of confusion is the difference between IDC and Ductal Carcinoma In Situ (DCIS).

  • DCIS (Non-Invasive): The cancer cells are still “in situ” (in their original place), meaning they are trapped inside the milk ducts and have not yet grown into the surrounding tissue [4][8].
  • IDC (Invasive): The cells have broken through the “basement membrane” (the wall of the duct) and moved into the stroma (the surrounding fatty and connective tissue) [3][4].

While DCIS is often considered a “pre-cancer” or a non-obligate precursor, IDC requires a different treatment approach because invasive cells have the potential to travel to other parts of the body [9][10]. It is very common for both IDC and DCIS to be found together in the same tumor; in one large study, over 60% of patients with invasive ductal carcinoma also had a DCIS component [11].

Why This Diagnosis Is Not “One-Size-Fits-All”

While many people share the diagnosis of IDC, the biology of the tumor can vary significantly from person to person. Doctors look at several factors to “fingerprint” your specific cancer:

  • Receptor Status: They test for Estrogen Receptors (ER), Progesterone Receptors (PR), and HER2 [12][13]. These “receptors” act like ears on the cancer cell, listening for signals to grow. Knowing which receptors your cancer has tells your team which medicines will block those signals [14][15].
  • Grade: The Nottingham grade describes how much the cancer cells look like normal breast cells [16]. Lower-grade cells look more normal and usually grow more slowly, while higher-grade cells look more abnormal-looking and may grow faster [17].
  • Heterogeneity: This is a medical term for “diversity” [18]. Even within a single tumor, cells can behave differently, which is why your team may recommend multiple types of treatment to target the cancer effectively [19].

Common Misunderstandings About Treatment

Early in a diagnosis, it is easy to assume that surgery is the only or the most important treatment. However, modern care for IDC is usually multimodal, meaning it uses a combination of different tools [20]:

  1. Local Treatment (Surgery and Radiation): These focus on removing or destroying the cancer in the breast itself and local lymph nodes [21].
  2. Systemic Treatment (Chemotherapy, Hormone Therapy, or Targeted Therapy): These are medicines that travel through your entire body to find and treat any cancer cells that may have strayed from the original site [22][23].

Choosing a more extensive surgery (like a mastectomy) over a smaller one (like a lumpectomy) does not always lead to a better long-term outcome [21]. Your care team will recommend a plan based on the specific “fingerprint” of your IDC to provide you with the best possible protection while preserving your quality of life.

Common questions in this guide

What does an invasive ductal carcinoma diagnosis mean?
It means cancer began in a milk duct and grew through the duct wall into nearby breast tissue. The word “invasive” does not by itself mean the cancer has reached distant organs or is stage IV; staging tests and lymph-node evaluation show how far it has spread.
Is invasive ductal carcinoma also called IBC-NST?
Yes. Invasive breast carcinoma of no special type, abbreviated IBC-NST, is the modern classification often used for what has traditionally been called invasive ductal carcinoma. “No special type” means the cells do not have the distinctive features of certain rarer breast cancer subtypes.
How is IDC different from DCIS?
DCIS remains inside the milk ducts, while IDC has broken through the duct wall into surrounding tissue. Because invasive cells can travel beyond the original site, IDC generally requires a different treatment approach, although both can be present in one tumor.
What do ER, PR, and HER2 results tell me?
They identify growth-related receptors on the cancer cells. ER and PR results help show whether hormone therapy may be useful, while HER2 results help guide targeted treatment; together, these results help your team select medicines for your cancer.
Why does the Nottingham grade matter?
The Nottingham grade describes how much the cancer cells resemble normal breast cells. Lower-grade tumors usually look more like normal cells and tend to grow more slowly, while higher-grade tumors look more abnormal and may grow faster; the grade is one factor used when planning treatment.
Why might IDC treatment include surgery plus other therapies?
Surgery and radiation treat the breast and nearby lymph-node area, while chemotherapy, hormone therapy, and targeted therapy travel through the body to address cancer cells that may have moved beyond the original tumor. Combining local and systemic treatments can provide a more complete plan, but the right combination depends on the tumor’s stage, grade, and receptor results.
Does a mastectomy always work better than a lumpectomy for IDC?
No. A more extensive operation does not automatically lead to a better long-term outcome than a smaller operation, and the recommendation depends on the tumor and your overall treatment plan. Ask your breast cancer team how surgery, radiation, and systemic therapy fit together in your case.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report use the term 'Invasive Ductal Carcinoma' or 'Invasive Breast Carcinoma of No Special Type'?
  2. 2.What was the size of the invasive part of the tumor, and did you find any signs of lymphovascular invasion?
  3. 3.Was there any Ductal Carcinoma In Situ (DCIS) found alongside the invasive cancer?
  4. 4.What is my tumor's grade (Nottingham grade), and how does that affect my treatment plan?
  5. 5.Are my hormone receptors (ER and PR) and HER2 status confirmed, and what do those results mean for the type of therapy you're recommending?
  6. 6.Why is a 'multimodal' treatment approach (like combining surgery with other therapies) being recommended for my specific case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Invasive Lobular Carcinoma of the Breast with Extracellular Mucin: Case Report of a New Variant of Lobular Carcinoma of the Breast.

    Boukhechba M, Kadiri H, El Khannoussi B

    Case reports in pathology 2018; (2018()):5362951 doi:10.1155/2018/5362951.

    PMID: 29850340
  2. 2

    Retrospective evaluation of histopathological examinations in invasive ductal breast cancer of no special type: an analysis of 691 patients.

    Badowska-Kozakiewicz AM, Liszcz A, Sobol M, Patera J

    Archives of medical science : AMS 2017; (13(6)):1408-1415 doi:10.5114/aoms.2015.53964.

    PMID: 29181072
  3. 3

    Special Histologic Type and Rare Breast Tumors - Diagnostic Review and Clinico-Pathological Implications.

    Tan BY, Lim EH, Tan PH

    Surgical pathology clinics 2022; (15(1)):29-55 doi:10.1016/j.path.2021.11.003.

    PMID: 35236633
  4. 4

    p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

    Lodillinsky C, Infante E, Guichard A, et al.

    Oncogene 2016; (35(3)):344-57 doi:10.1038/onc.2015.87.

    PMID: 25893299
  5. 5

    Invasive breast cancer: Current perspectives and emerging views.

    Shea EKH, Koh VCY, Tan PH

    Pathology international 2020; (70(5)):242-252 doi:10.1111/pin.12910.

    PMID: 32039524
  6. 6

    Diagnostically Challenging Subtypes of Invasive Lobular Carcinomas: How to Avoid Potential Diagnostic Pitfalls.

    Koufopoulos N, Pateras IS, Gouloumis AR, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(11)) doi:10.3390/diagnostics12112658.

    PMID: 36359501
  7. 7

    Epidemiological and molecular profile of breast cancer: a retrospective study in Casablanca, Morocco.

    Khadiri K, Khadrouf Z, Mellouki A, et al.

    The Pan African medical journal 2025; (50()):105 doi:10.11604/pamj.2025.50.105.43868.

    PMID: 40656144
  8. 8

    Single Cell Expression Analysis of Ductal Carcinoma in Situ Identifies Complex Genotypic-Phenotypic Relationships Altering Epithelial Composition.

    Qin X, Strand SH, Lee MR, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2023.10.10.561724.

    PMID: 39386437
  9. 9

    Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer.

    Yan F, Göransson S, Olofsson H, et al.

    Cell communication and signaling : CCS 2025; (23(1)):269 doi:10.1186/s12964-025-02276-y.

    PMID: 40468448
  10. 10

    Modeling Human Ductal Carcinoma In Situ in the Mouse.

    Behbod F, Gomes AM, Machado HL

    Journal of mammary gland biology and neoplasia 2018; (23(4)):269-278 doi:10.1007/s10911-018-9408-0.

    PMID: 30145750
  11. 11

    The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis.

    Chen H, Bai F, Wang M, et al.

    Annals of translational medicine 2019; (7(18)):484 doi:10.21037/atm.2019.08.16.

    PMID: 31700920
  12. 12

    A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India.

    Somal PK, Sancheti S, Sharma A, et al.

    South Asian journal of cancer 2023; (12(2)):104-111 doi:10.1055/s-0043-1761942.

    PMID: 37969672
  13. 13

    Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.

    Gordian-Arroyo AM, Zynger DL, Tozbikian GH

    American journal of clinical pathology 2019; (152(1)):17-26 doi:10.1093/ajcp/aqz012.

    PMID: 30958889
  14. 14

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

    Wolff AC, Somerfield MR, Dowsett M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

    PMID: 37284804
  15. 15

    Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.

    Ivanova M, Porta FM, D'Ercole M, et al.

    Virchows Archiv : an international journal of pathology 2024; (484(1)):3-14 doi:10.1007/s00428-023-03656-w.

    PMID: 37770765
  16. 16

    The clinical significance of HER2 expression in DCIS.

    Akrida I, Mulita F

    Medical oncology (Northwood, London, England) 2022; (40(1)):16 doi:10.1007/s12032-022-01876-9.

    PMID: 36352293
  17. 17

    Molecular phenotypes of DCIS predict overall and invasive recurrence.

    Williams KE, Barnes NLP, Cramer A, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(5)):1019-1025 doi:10.1093/annonc/mdv062.

    PMID: 25678586
  18. 18

    Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.

    Tokura M, Nakayama J, Prieto-Vila M, et al.

    Cancer research 2022; (82(18)):3236-3248 doi:10.1158/0008-5472.CAN-22-0090.

    PMID: 35852797
  19. 19

    Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in situ and Invasive Components in Breast Carcinoma.

    Naimi A, Mohaghegh N

    Iranian journal of pathology 2024; (19(3)):318-325 doi:10.30699/IJP.2024.2025907.3285.

    PMID: 39687455
  20. 20

    Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?

    Rosso KJ, Weiss A, Thompson AM

    Surgical oncology clinics of North America 2018; (27(1)):69-80 doi:10.1016/j.soc.2017.08.002.

    PMID: 29132566
  21. 21

    Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study.

    Mannu GS, Wang Z, Dodwell D, et al.

    BMJ (Clinical research ed.) 2024; (384()):e075498 doi:10.1136/bmj-2023-075498.

    PMID: 38267073
  22. 22

    [Update of the German S3 breast cancer guideline : What is new for pathologists?]

    Lebeau A, Denkert C, Sinn P, et al.

    Der Pathologe 2019; (40(2)):185-198 doi:10.1007/s00292-019-0578-3.

    PMID: 30847505
  23. 23

    Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

    Bardia A, Hu X, Dent R, et al.

    The New England journal of medicine 2024; (391(22)):2110-2122 doi:10.1056/NEJMoa2407086.

    PMID: 39282896

This page explains invasive ductal carcinoma, diagnostic markers, and treatment approaches for informational purposes only; it does not constitute medical advice. Your breast cancer team should interpret your pathology and staging results and recommend care for your situation.

Get notified when new evidence is published on breast ductal adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.